



Title **Vertebral Axial Decompression (VAX-D) Therapy for Chronic Low Back Pain, April 2001**

Agency **MSAC, Medicare Services Advisory Committee**
Commonwealth Department of Health and Ageing,
GPO Box 9848 Canberra ACT 2601 Australia;
tel: +61 2 6289 6811, fax: +61 2 6289 8799, <http://www.msac.gov.au>

Reference MSAC Application number 1012. Assessment report ISSN 1443-7120

Aim

To assess the safety and effectiveness of vertebral axial decompression (VAX-D) therapy and under what circumstances public funding should be supported for this service.

Conclusions and results

Safety: Detailed evidence on the safety and complication rates of the VAX-D table is lacking.

Effectiveness: For patients with radiculopathy or radicular pain associated with a herniated intervertebral disc, there is some evidence to suggest that surgical discectomy is more effective than VAX-D therapy at relieving pain in the short to medium term. No comparisons can be made between these two therapies in this patient group over the long term (ie, 10 years). For other patient groups (ie, patients with radiculopathy or radicular pain associated with degenerated intervertebral discs, and patients with non-specific low back pain) the evidence is insufficient to make any conclusions regarding the relative effectiveness of VAX-D therapy.

Cost effectiveness: No evidence based conclusions can be drawn regarding the cost effectiveness of VAX-D therapy in any patient group. However, it is likely that discectomy is more cost effective than VAX-D therapy for treating patients with radiculopathy or radicular pain associated with herniated intervertebral discs.

Recommendations

As there is currently insufficient evidence pertaining to the effectiveness of VAX-D therapy, MSAC recommended that public funding should not be supported at this time for this procedure.

Method

The applicant requested that VAX-D therapy be subsidized for the treatment of chronic low back pain resistant to conservative treatment. Accordingly, a review of the medical literature was limited to evidence of second-line treatment administered to patients with low back pain of at least 3 months duration. Three distinct patient groups were identified (see table below), and each of these groups was associated with a particular treatment. In this review, the most common conservative treatment for non-specific low back pain was defined as oral analgesics or non-steroidal anti-inflammatory drugs (NSAIDs), with or without physiotherapy. In addition to evaluating the evidence pertaining to VAX-D therapy in each of the three patient groups, the evaluation included a review of evidence related to each of the three comparator treatments.